These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 21435267

  • 1. Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
    Feriani M, De Meester JM, McMahon LP, Rottembourg JB, Bridges I, Farouk M, Pronai W.
    BMC Nephrol; 2011 Mar 24; 12():13. PubMed ID: 21435267
    [Abstract] [Full Text] [Related]

  • 2. An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months.
    Rottembourg JB, Bridges I, Pronai W, Feriani M, McMahon LP, De Meester JM, Farouk M, Molemans B.
    Clin Nephrol; 2011 Mar 24; 75(3):242-50. PubMed ID: 21329635
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Mar 24; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 4. The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.
    Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR.
    Wien Klin Wochenschr; 2013 Feb 24; 125(3-4):71-82. PubMed ID: 23299452
    [Abstract] [Full Text] [Related]

  • 5. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M.
    Nephrol Dial Transplant; 2012 Jun 24; 27(6):2303-11. PubMed ID: 22140136
    [Abstract] [Full Text] [Related]

  • 6. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Jun 24; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 7. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun 24; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 24; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 9. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, Shavkin A, Srivaths P, Wong CJ, Petersen J.
    Pediatr Nephrol; 2018 Jan 24; 33(1):125-137. PubMed ID: 28815341
    [Abstract] [Full Text] [Related]

  • 10. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 11. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov 25; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study.
    Disney A, Jersey PD, Kirkland G, Mantha M, Charlesworth JA, Gallagher M, Harris D, Gock H, Mangos GJ, Macmillan J, Liu W, Viswalingam A.
    Nephrology (Carlton); 2007 Feb 25; 12(1):95-101. PubMed ID: 17295668
    [Abstract] [Full Text] [Related]

  • 13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Feb 25; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 14. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Feb 25; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 15. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Feb 25; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Feb 25; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 25; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 18. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY, Chu TS, Huang JW, Wu MS, Wu KD.
    J Formos Med Assoc; 2008 Nov 25; 107(11):843-50. PubMed ID: 18971153
    [Abstract] [Full Text] [Related]

  • 19. Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis.
    Trachsler J, Glück Z, Dickenmann M, Gauthier T, Brünisholz M, Martin PY, Burnier M, Wahl C, Wüthrich RP.
    Clin Nephrol; 2009 Jun 25; 71(6):697-702. PubMed ID: 19473639
    [Abstract] [Full Text] [Related]

  • 20. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
    Al Raisi F, Al Salmi I, Kamble P, Al Shehri M, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2016 Jun 25; 27(6):1182-1187. PubMed ID: 27900963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.